Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132)
This study has been completed.
First Received: September 12, 2005   Last Updated: July 17, 2008   History of Changes
Sponsored by: ALTANA Pharma
Information provided by: ALTANA Pharma
ClinicalTrials.gov Identifier: NCT00163358
  Purpose

The aim of the study is to compare the efficacy of ciclesonide versus fixed combination of fluticasone propionate/salmeterol versus placebo, on long-term asthma control in patients with mild persistent asthma. The study duration consists of a baseline period (2 weeks) and a treatment period (12 months).

The study will provide further data on safety and tolerability of ciclesonide.


Condition Intervention Phase
Asthma
Drug: Ciclesonide
Phase III

MedlinePlus related topics: Asthma
Drug Information available for: Fluticasone propionate Salmeterol Fluticasone Salmeterol xinafoate Ciclesonide
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Efficacy of Ciclesonide and of a Fixed Combination With Fluticasone Propionate and Salmeterol Versus Placebo on Long-Term Asthma Control

Further study details as provided by ALTANA Pharma:

Primary Outcome Measures:
  • time until the first severe asthma exacerbation occurs
  • number of poorly controlled asthma days.

Secondary Outcome Measures:
  • percentage of days with asthma control
  • percentage of days with asthma symptoms
  • percentage of nocturnal awakenings due to asthma
  • asthma symptom score
  • number of inhalations of rescue medication
  • proportion of patients with severe asthma exacerbations
  • differences in morning PEF from diary
  • differences in FEV1 and FVC from spirometry
  • blood eosinophils
  • AQLQ(S)
  • health economic data
  • vital signs
  • laboratory work-up
  • adverse events.

Estimated Enrollment: 630
Study Start Date: September 2003
  Eligibility

Ages Eligible for Study:   12 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  • Clinical diagnosis of mild persistent asthma
  • Pre-treatment with SABAs only
  • FEV1 ≥80% predicted
  • Good health with the exception of asthma

Main Exclusion Criteria:

  • Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids
  • COPD (chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in pulmonary function
  • Pregnancy
  • Intention to become pregnant during the course of the study
  • Breast feeding
  • Lack of safe contraception
  • Current smokers ≥10 pack-years and ex-smokers with ≥10 pack-years
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00163358

  Hide Study Locations
Locations
Australia
Altana Pharma/Nycomed
Concord, Australia, 2139
Altana Pharma/Nycomed
Adelaide South Australia, Australia, 5000
Altana Pharma/Nycomed
CAMPERDOWN, Australia, NSW 2050
Altana Pharma/Nycomed
Burwood, Australia, NSW 2134
Altana Pharma/Nycomed
Bracken Ridge, Australia, QLD 4017
Altana Pharma/Nycomed
Kippa-ring, Australia, QLD 4021
Altana Pharma/Nycomed
Clayton, Australia, VIC 3168
Altana Pharma/Nycomed
Inala, Australia, QLD 4077
Altana Pharma/Nycomed
South Brisbane, Australia, QLD 4101
Altana Pharma/Nycomed
Carina Heights, Australia, QLD 4152
Altana Pharma/Nycomed
Wayville, Australia, SA 5034
Altana Pharma/Nycomed
Toorak Gardens, Australia, SA 5056
Altana Pharma/Nycomed
Auchenflower, Australia, QLD 4066
Altana Pharma/Nycomed
Geelong, Australia, VIC 3220
Altana Pharma/Nycomed
Rosebud, Australia, VIC 3939
Altana Pharma/Nycomed
Nedlands, Australia, WA 6009
Canada
Altana Pharma/Nycomed
Saint John's, Canada, A1A 3R5
Altana Pharma/Nycomed
St. John's, Canada, A1E 2C2
Altana Pharma/Nycomed
Saint John, Canada, E2K2T8
Altana Pharma/Nycomed
Les Saules, QC, Canada, G1P 1J6
Altana Pharma/Nycomed
Beaconsfield, QC, Canada, H9W2X3
Altana Pharma/Nycomed
Sainte-Foy, Quebec, Canada, G1V4G5
Altana Pharma/Nycomed
Quebec City, Canada, G8T 7A1
Altana Pharma/Nycomed
Montreal, PQ, Canada, H3H 1V4
Altana Pharma/Nycomed
Montreal, Canada, H4J1C5
Altana Pharma/Nycomed
Laval, Canada, H7V3Y7
Altana Pharma/Nycomed
Ste-Foy PQ, Canada, G1V 4M6
Altana Pharma/Nycomed
Cowansville, Canada, J2K2X9
Altana Pharma/Nycomed
Longueuil, PQ, Canada, J4N 1E1
Altana Pharma/Nycomed
Ottawa, Canada, K1Y 4G2
Altana Pharma/Nycomed
Kingston, Ontario, Canada, K7L 2V6
Altana Pharma/Nycomed
North York, Canada, M3H 3S3
Altana Pharma/Nycomed
Toronto, Canada, M4N3N5
Altana Pharma/Nycomed
Toronto, Canada, M4P1P2
Altana Pharma/Nycomed
Langley BC, Canada, V3A 4H9
Altana Pharma/Nycomed
Toronto, Canada, M9W 4L6
Altana Pharma/Nycomed
Corner Brook, Canada, NFLD
Altana Pharma/Nycomed
North Bay, Canada, P1B2H3
Altana Pharma/Nycomed
Saskatoon, SK, Canada, S7K 3H3
Altana Pharma/Nycomed
Penticton, BC, Canada, V2A 5C8
Altana Pharma/Nycomed
Toronto ON, Canada, M5S 2A5
Altana Pharma/Nycomed
Coquitlam, Canada, V3K 3P4
Altana Pharma/Nycomed
Coquitlam, BC, Canada, V3K 3V9
Czech Republic
Altana Pharma/Nycomed
Praha 10, Czech Republic, 100 00
Altana Pharma/Nycomed
Praha 2, Czech Republic, 128 00
Altana Pharma/Nycomed
Praha 4, Czech Republic, 14046
Altana Pharma/Nycomed
Praha 8, Czech Republic, 181 00
Altana Pharma/Nycomed
Praha 9, Czech Republic, 190 61
Altana Pharma/Nycomed
Karlovy Vary, Czech Republic, 360 00
Altana Pharma/Nycomed
Pribram VI, Czech Republic, 261 05
Altana Pharma/Nycomed
Beroun, Czech Republic, 266 01
Altana Pharma/Nycomed
Kladno, Czech Republic, 272 01
Altana Pharma/Nycomed
Kutná Hora, Czech Republic, 28401
Altana Pharma/Nycomed
Rokycany, Czech Republic, 337 01
Altana Pharma/Nycomed
Príbram VIII, Czech Republic, 261 01
Altana Pharma/Nycomed
Jindrichuv Hradec, Czech Republic, 377 01
Altana Pharma/Nycomed
Strakonice, Czech Republic, 38601
Altana Pharma/Nycomed
Usti nad Labem, Czech Republic, 401 13
Altana Pharma/Nycomed
Ceska Lipa, Czech Republic, 470 01
Altana Pharma/Nycomed
Havlickuv, Czech Republic, 580 01
Altana Pharma/Nycomed
Trutnov, Czech Republic, 54101
Altana Pharma/Nycomed
Cvikov, Czech Republic, 471 54
Altana Pharma/Nycomed
Jihlava, Czech Republic, 58601
Altana Pharma/Nycomed
Ostrava-Marián.Hory, Czech Republic, 70030
Hungary
Altana Pharma/Nycomed
Budapest, Hungary, 1046
Altana Pharma/Nycomed
Budapest XI, Hungary, 1117
Altana Pharma/Nycomed
Budapet, Hungary, 1529
Altana Pharma/Nycomed
Budapest, Hungary, 1529
Altana Pharma/Nycomed
Budapest, Hungary, 1134
Altana Pharma/Nycomed
Tatabanya, Hungary, 2800
Altana Pharma/Nycomed
Nyíregyháza, Hungary, 4400
Altana Pharma/Nycomed
Szarvas, Hungary, 5540
Altana Pharma/Nycomed
Kecskemet, Hungary, 6000
Poland
Altana Pharma/Nycomed
Rzeszow, Poland, 35-302
Altana Pharma/Nycomed
Rzeszow, Poland, 35-068
Altana Pharma/Nycomed
Warszawa, Poland, 01-138
Altana Pharma/Nycomed
Wroclaw, Poland, 50-417
Altana Pharma/Nycomed
Wroclaw, Poland, 53-674
Altana Pharma/Nycomed
Bydgoszcz, Poland, 85-091
Altana Pharma/Nycomed
Bydgoszcz, Poland, 85-681
Altana Pharma/Nycomed
Lódz', Poland, 90-153
Altana Pharma/Nycomed
Lodz, Poland, 91-520
South Africa
Altana Pharma/Nycomed
Arcadia, Pretoria, South Africa, 132
Altana Pharma/Nycomed
Daveyton, South Africa, 1520
Altana Pharma/Nycomed
Centurion, Pretoria, South Africa, 157
Altana Pharma/Nycomed
Midrand, South Africa, 1685
Altana Pharma/Nycomed
Pretoria, South Africa, 186
Altana Pharma/Nycomed
Berea, Durban, South Africa, 4000
Altana Pharma/Nycomed
Durban, Amanzimtoti, South Africa, 4126
Altana Pharma/Nycomed
George, South Africa, 6539
Altana Pharma/Nycomed
Bloemfontein, South Africa, 9301
Altana Pharma/Nycomed
Bellville, Cape Town, South Africa, 7530
Altana Pharma/Nycomed
Paarl, South Africa, 7646
Altana Pharma/Nycomed
Cape Town, South Africa, 7764
Altana Pharma/Nycomed
Mowbray, Cape Town, South Africa, 7925
Altana Pharma/Nycomed
Bloemfontein, South Africa, 9300
Altana Pharma/Nycomed
Panorama / RSA-Cape Town, South Africa, 7500
Spain
Altana Pharma/Nycomed
Barcelona, Spain, 8222
Altana Pharma/Nycomed
Peralada (Girona), Spain, 17491
Altana Pharma/Nycomed
Campdevanol (Girona), Spain, 17530
Altana Pharma/Nycomed
Guadalajara, Spain, 19002
Altana Pharma/Nycomed
Leganes (Madrid), Spain, 28914
Altana Pharma/Nycomed
Alcorcón (Madrid), Spain, 28922
Altana Pharma/Nycomed
Alicante, Spain, 3001
Altana Pharma/Nycomed
San Vicente del Raspeig (Alicante), Spain, 3187
Altana Pharma/Nycomed
Alicante, Spain, 3540
Altana Pharma/Nycomed
Elda (Alicante), Spain, 3600
Altana Pharma/Nycomed
Petrer (Alicante), Spain, 3610
Altana Pharma/Nycomed
Valencia, Spain, 46017
Altana Pharma/Nycomed
Palma de Mallorca, Spain, 7014
Altana Pharma/Nycomed
Santiago de Compostela, Spain, 15706
Sponsors and Collaborators
ALTANA Pharma
Investigators
Study Chair: Paul O'Byrne, Prof. McMaster University in Hamilton, Ontario, Canada
Study Chair: Søren Pedersen, Prof. University of Odense, Kolding, Denmark
Study Chair: D.S. Postma, Prof. University Hospital of Groningen, The Netherlands
  More Information

No publications provided

Study ID Numbers: BY9010/M1-132
Study First Received: September 12, 2005
Last Updated: July 17, 2008
ClinicalTrials.gov Identifier: NCT00163358     History of Changes
Health Authority: Canada: Health Canada

Keywords provided by ALTANA Pharma:
Asthma
Ciclesonide
Fluticasone propionate
Salmeterol

Study placed in the following topic categories:
Anti-Inflammatory Agents
Neurotransmitter Agents
Salmeterol
Bronchial Diseases
Adrenergic Agents
Adrenergic beta-Agonists
Ciclesonide
Anti-Asthmatic Agents
Asthma
Anti-Allergic Agents
Adrenergic Agonists
Lung Diseases, Obstructive
Hypersensitivity
Respiratory Tract Diseases
Lung Diseases
Hypersensitivity, Immediate
Fluticasone
Peripheral Nervous System Agents
Bronchodilator Agents
Respiratory Hypersensitivity

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Respiratory System Agents
Neurotransmitter Agents
Bronchial Diseases
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Ciclesonide
Physiological Effects of Drugs
Adrenergic Agonists
Hypersensitivity
Lung Diseases, Obstructive
Respiratory Tract Diseases
Therapeutic Uses
Fluticasone
Dermatologic Agents
Salmeterol
Adrenergic beta-Agonists
Immune System Diseases
Asthma
Anti-Asthmatic Agents
Anti-Allergic Agents
Pharmacologic Actions
Autonomic Agents
Lung Diseases
Hypersensitivity, Immediate
Peripheral Nervous System Agents
Bronchodilator Agents
Respiratory Hypersensitivity

ClinicalTrials.gov processed this record on May 11, 2009